ArticlePharmacogenomics and personalized medicine2018
Article in Pharmacogenomics and personalized medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Executive summary of the guideline for prescribing opioid analgesics for chronic non-cancer pain (third edition) by the Japan Society of Pain Clinicians.Journal of anesthesia · 2025Guideline
- Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study.International journal of molecular sciences · 2023Trial
- Review
- Advancements in pathology: Digital transformation, precision medicine, and beyond.Journal of pathology informatics · 2025Review
- Opioid Monitoring in Clinical Settings: Strategies and Implications of Tailored Approaches for Therapy.International journal of molecular sciences · 2024Review
- Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of PreemptiveJournal of pain research · 2024Article
- Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Protocol for Biospecimen Collection and Analysis Within the BACPAC Research Program.Pain medicine (Malden, Mass.) · 2023Article
- Association ofAnnals of translational medicine · 2022Article
- Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.The oncologist · 2021Article
- Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics.Pharmaceutics · 2021Review
- Resolving discordantPharmacogenomics · 2021Article
- Pharmacogenomics of oxycodone: a narrative literature review.Pharmacogenomics · 2021Review
- Different Pharmacokinetics of Tramadol,Frontiers in pharmacology · 2021Article
- No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study.Pharmacogenomics and personalized medicine · 2021Article
- An update on drug-drug interactions between antiretroviral therapies and drugs of abuse in HIV systems.Expert opinion on drug metabolism & toxicology · 2020Review
- Can Implementation of Genetics and Pharmacogenomics Improve Treatment of Chronic Low Back Pain?Pharmaceutics · 2020Review
- Review
- Genetic contribution to lipid target achievement with statin therapy: a prospective study.The pharmacogenomics journal · 2020Observational
- A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.Medicina (Kaunas, Lithuania) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOpioids are widely used for chronic low back pain (CLBP); however, it is still unclear how to predict their effectiveness and safety. Codeine, tramadol and oxycodone are metabolized by CYP/CYP450 2D6 (CYP2D6), a highly polymorphic enzyme linked to allele-specific related differences in metabolic activity. PURPOSE: PATIENTS AND
methodsA cohort of 224 Italian patients with CLBP treated with codeine or oxycodone was retrospectively evaluated to determine whether adverse reactions and effectiveness were related to
results
conclusionOur results showed that reduced CYP2D6 activity is correlated with lack of therapeutic effect. We found that the pharmacogenetic analysis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.